calcitonin and Adenoma

calcitonin has been researched along with Adenoma* in 4 studies

Other Studies

4 other study(ies) available for calcitonin and Adenoma

ArticleYear
Treatment of extreme hypercalcaemia: the role of haemodialysis.
    BMJ case reports, 2018, Jun-04, Volume: 2018

    A patient with extremely high calcium level of 23.9 mg/dL (5.97 mmol/L) was admitted to our department unconscious with pathological ECG recording, demonstrating shortening of QT interval. The patient was treated by fluid resuscitation, bisphosphonates, salmon calcitonin and steroids. Haemodialysis with low calcium bath had been promptly provided with improvement of consciousness and calcium level. ECG changes disappeared. Subsequent investigations revealed hyperparathyroidism and a large parathyroid adenoma was then surgically removed. Extreme and rapid calcium elevation (parathyroid crisis) is rarely seen in primary hyperparathyroidism and usually is distinctive for malignancy. In the context of acute kidney injury and refractory hypercalcaemia with life-threatening complications (coma, ECG changes with impending danger of arrhythmia), haemodialysis may effectively decrease calcium levels. It should be pointed out that dialysis is an efficient method of treatment of refractory hypercalcaemia, parathyroid crisis, but it is rarely used due to its invasive nature.

    Topics: Adenoma; Aged; Bone Density Conservation Agents; Calcitonin; Dexamethasone; Diphosphonates; Fluid Therapy; Glucocorticoids; Humans; Hypercalcemia; Male; Pamidronate; Parathyroid Neoplasms; Prednisone; Renal Dialysis; Severity of Illness Index; Tomography, X-Ray Computed

2018
Recurrent pancreatitis induced by hyperparathyroidism in pregnancy.
    Archives of gynecology and obstetrics, 2011, Volume: 284, Issue:3

    As primary hyperparathyroidism affects mainly middle-aged and elderly women, it is an infrequent finding during gestation and breastfeeding. To date, less than 200 pregnant patients with primary hyperparathyroidism diagnosed during pregnancy have been described. Like in other disorders of the parathyroid gland, the recognition of primary hyperparathyroidism during pregnancy and lactation may be difficult, as clinical symptoms are not specific, while laboratory findings may be masked by some typical pregnancy-induced changes in calcium and phosphate homeostasis. If remains untreated, the disease may result in serious clinical implications for the mother and fetus. Most authors consider surgery within the second trimester of pregnancy as the treatment of choice in this group of patients.. In our paper, we discuss the case of a 35-year-old female with a history of recurrent acute pancreatitis and recurrent abortions. As the patient declined surgery, conservative management with calcitonin was started and continued throughout the rest of pregnancy, and led to giving birth to the infant whose only health problem was transient hypocalcemia.. The described case shows that conservative management, if started respectively early and conducted on the basis of a patient's condition, may effectively reduce increased perinatal and maternal morbidity and mortality in pregnant women declining surgery.

    Topics: Abortion, Habitual; Adenoma; Adult; Calcitonin; Calcium Gluconate; Female; Humans; Hypercalcemia; Hyperparathyroidism; Infant, Newborn; Pancreatitis; Parathyroid Neoplasms; Pregnancy; Pregnancy Complications; Recurrence

2011
Salmon calcitonin induces pituitary tumor in rats.
    Endocrinologia japonica, 1991, Volume: 38, Issue:6

    Calcitonin is widely used in the treatment of post-menopausal osteoporosis. The present study was designed to investigate the effects of salmon calcitonin (SCT) on the incidence of the pituitary tumors in Sprague-Dawley (SD) rats. Subcutaneous injections of SCT at a dose of 160 IU/kg/day for 6 months reduced body weight and induced one pituitary hyperplasia and three pituitary adenomas in 4 of 5 animals, while 5 controls did not show any changes. Prolactin-positive cells were located at the periphery of the affected pituitaries adjacent to the prolactin-negative adenomas. In addition, serum concentrations of prolactin and TSH were lower than in the controls, although serum calcium or LH levels were not significantly different from the controls. Among 7 animals treated with SCT for 6 months followed by no medication for another 6 months, 5 adenomas were detected, one of which had invasive growth toward the adjacent tissue, whereas only one adenoma was found in 9 controls. These results suggest that SCT administration at a high dose may induce the formation of pituitary adenoma, or may accelerate the development of spontaneous pituitary adenomas, some of which show frequent mitotic figures and invasive growth into the surrounding tissue, possibly resulting in malignant transformation. This indicates the need for caution in considering whether calcitonin injections into patients with osteoporosis as well as Paget's disease may induce such pituitary tumors.

    Topics: Adenoma; Animals; Calcitonin; Calcium; Dose-Response Relationship, Drug; Injections, Subcutaneous; Luteinizing Hormone; Male; Organ Size; Pituitary Gland; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Rats; Rats, Inbred Strains; Thyrotropin

1991
Studies on in vivo and in vitro release of intact parathyroid hormone using a new two-site immunochemiluminometric assay.
    World journal of surgery, 1988, Volume: 12, Issue:4

    Topics: Adenoma; Adult; Aged; Calcitonin; Calcium; Female; Fluorescent Antibody Technique; Humans; Hypercalcemia; Hyperparathyroidism; Hyperplasia; In Vitro Techniques; Kidney Failure, Chronic; Luminescent Measurements; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms

1988